{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T06:22:41Z","timestamp":1789885361295,"version":"4.0.1"},"reference-count":40,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T00:00:00Z","timestamp":1467936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Science Foundation of China","doi-asserted-by":"publisher","award":["81172276"],"award-info":[{"award-number":["81172276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>The data regarding the prognostic significance of EGFR (epidermal growth factor receptor) expression and adjuvant therapy in patients with resected pancreatic cancer are insufficient. We retrospectively investigated EGFR status in 357 resected PDAC (pancreatic duct adenocarcinoma) patients using tissue immunohistochemistry and validated the possible role of EGFR expression in predicting prognosis. The analysis was based on excluding the multiple confounding parameters. A negative association was found between overall EGFR status and postoperative survival (p = 0.986). Remarkably, adjuvant chemotherapy and radiotherapy were significantly associated with favorable postoperative survival, which prolonged median overall survival (OS) for 5.8 and 10.2 months (p = 0.009 and p = 0.006, respectively). Kaplan\u2013Meier analysis showed that adjuvant chemotherapy correlated with an obvious survival benefit in the EGFR-positive subgroup rather than in the EGFR-negative subgroup. In the subgroup analyses, chemotherapy was highly associated with increased postoperative survival in the EGFR-positive subgroup (p = 0.002), and radiotherapy had a significant survival benefit in the EGFR-negative subgroup (p = 0.029). This study demonstrated that EGFR expression is not correlated with outcome in resected pancreatic cancer patients. Adjuvant chemotherapy and radiotherapy were significantly associated with improved survival in contrary EGFR expressing subgroup. Further studies of EGFR as a potential target for pancreatic cancer treatment are warranted.<\/jats:p>","DOI":"10.3390\/ijms17071090","type":"journal-article","created":{"date-parts":[[2016,7,8]],"date-time":"2016-07-08T09:46:07Z","timestamp":1467971167000},"page":"1090","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Prognostic and Predictive Role of Epidermal Growth Factor Receptor in Surgical Resected Pancreatic Cancer"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8807-5001","authenticated-orcid":false,"given":"Meng","family":"Guo","sequence":"first","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopei","family":"Luo","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Liu","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Cheng","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lu","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaizhou","family":"Jin","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Long","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Xu","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"},{"name":"Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanxing","family":"Ni","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianjun","family":"Yu","sequence":"additional","affiliation":[{"name":"Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China"},{"name":"Department of Pancreas Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China"},{"name":"Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2016,7,8]]},"reference":[{"key":"ref_1","first-page":"2140","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Moyer","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/caac.21254","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1056\/NEJMc1412266","article-title":"Pancreatic adenocarcinoma","volume":"371","author":"Bukki","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3322\/caac.21190","article-title":"Recent progress in pancreatic cancer","volume":"63","author":"Wolfgang","year":"2013","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11912-011-0164-1","article-title":"Current treatment options for pancreatic carcinoma","volume":"13","author":"Castellanos","year":"2011","journal-title":"Curr. Oncol. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/00006676-200407000-00061","article-title":"The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: Poor prognosis in patients with pancreatic ductal adenocarcinoma","volume":"29","author":"Ueda","year":"2004","journal-title":"Pancreas"},{"key":"ref_7","first-page":"419","article-title":"Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy","volume":"3","author":"Faller","year":"2009","journal-title":"Biol. Targets Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa032295","article-title":"A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer","volume":"350","author":"Neoptolemos","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/annonc\/mdg207","article-title":"Adjuvant therapy in pancreatic cancer: Historical and current perspectives","volume":"14","author":"Neoptolemos","year":"2003","journal-title":"Ann. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/jso.23951","article-title":"Prognostic significance of DNA cytometry for adjuvant therapy response in pancreatic cancer","volume":"112","author":"Klein","year":"2015","journal-title":"J. Surg. Oncol."},{"key":"ref_11","first-page":"1579","article-title":"EGFR antagonists in cancer treatment (vol 358, pg 1160, 2008)","volume":"360","author":"Ciardello","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"Drug therapy: EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","article-title":"Epidermal growth factor-related peptides and their receptors in human malignancies","volume":"19","author":"Salomon","year":"1995","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_14","first-page":"277","article-title":"The receptor for EGF and its ligands\u2014Expression, prognostic value and target for therapy in cancer (review)","volume":"4","author":"Modjtahedi","year":"1994","journal-title":"Int. J. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000018737","article-title":"Molecular aspects of pancreatic cancer and future perspectives","volume":"16","author":"Friess","year":"1999","journal-title":"Dig. Surg."},{"key":"ref_16","first-page":"305","article-title":"Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis","volume":"11","author":"Tobita","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"ref_17","first-page":"629","article-title":"High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy","volume":"38","author":"Fujita","year":"2011","journal-title":"Int. J. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"6529","DOI":"10.1158\/1078-0432.CCR-14-0970","article-title":"Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery","volume":"20","author":"Li","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_19","first-page":"681","article-title":"Induction of ductal and stromal hyperplasia by basic fibroblast growth factor produced by human pancreatic carcinoma","volume":"19","author":"Kuniyasu","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3892\/etm.2012.518","article-title":"Membranous and cytoplasmic expression of epidermal growth factor receptor in metastatic pancreatic ductal adenocarcinoma","volume":"3","author":"Einama","year":"2012","journal-title":"Exp. Ther. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1002\/cncr.26661","article-title":"Epidermal growth factor receptor and insulinlike growth factor 1 receptor expression predict poor survival in pancreatic ductal adenocarcinoma","volume":"118","author":"Valsecchi","year":"2012","journal-title":"Cancer"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000093497","article-title":"Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique","volume":"23","author":"Bloomston","year":"2006","journal-title":"Dig. Surg."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1159\/000100917","article-title":"Long-term survival after radical resection for pancreatic head and ampullary cancer: A potential role for the EGF-R","volume":"24","author":"Smeenk","year":"2007","journal-title":"Dig. Surg."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1038\/bjc.2011.110","article-title":"Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer","volume":"104","author":"Smith","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1097\/00000658-200112000-00007","article-title":"Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and\/or chemotherapy in the ESPAC-1 randomized controlled trial","volume":"234","author":"Neoptolemos","year":"2001","journal-title":"Ann. Surg."},{"key":"ref_26","first-page":"61","article-title":"Pancreatic ductal adenocarcinoma: From genetics to biology to radiobiology to oncoimmunology and all the way back to the clinic","volume":"1855","author":"Fokas","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.bjc.6604936","article-title":"Biomarker analysis in stage III-IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: Epidermal growth factor receptor (EGFR) associated with favourable survival","volume":"100","author":"Kim","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdl300","article-title":"ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine","volume":"17","author":"Ceppi","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1002\/ijc.22129","article-title":"Molecular determinants of irinotecan efficacy","volume":"119","author":"Vallbohmer","year":"2006","journal-title":"Int. J. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.molmed.2015.04.001","article-title":"EGFR and NF-\u03baB: Partners in cancer","volume":"21","author":"Shostak","year":"2015","journal-title":"Trends Mol. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1038\/onc.2015.372","article-title":"The EGFR-HER2 module: A stem cell approach to understanding a prime target and driver of solid tumors","volume":"35","author":"Schneider","year":"2016","journal-title":"Oncogene"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1158\/1078-0432.CCR-14-0610","article-title":"Low expression of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition","volume":"21","author":"Kadera","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1093\/annonc\/mdt270","article-title":"Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP)","volume":"24","author":"Fensterer","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/annonc\/mdq384","article-title":"Multicenter phase II trial of adjuvant therapy for resected pancreatic cancer using cisplatin, 5-fluorouracil, and interferon-alfa-2b-based chemoradiation: ACOSOG Trial Z05031","volume":"22","author":"Picozzi","year":"2011","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1593\/tlo.10196","article-title":"A tolerability and pharmacokinetic study of adjuvant erlotinib and capecitabine with concurrent radiation in resected pancreatic cancer","volume":"3","author":"Ma","year":"2010","journal-title":"Transl. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/CAD.0b013e3283330590","article-title":"Epidermal growth factor receptor inhibitors in cancer treatment: Advances, challenges and opportunities","volume":"20","author":"Modjtahedi","year":"2009","journal-title":"Anti-Cancer Drug"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/j.ejca.2014.04.008","article-title":"A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer","volume":"50","author":"Renouf","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1517\/14656566.2015.1024654","article-title":"Systemic therapy for advanced pancreatic cancer: Individualising cytotoxic therapy","volume":"16","author":"Collins","year":"2015","journal-title":"Expert Opin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1200\/JCO.2004.12.040","article-title":"Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: A multicenter phase II Trial","volume":"22","author":"Xiong","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J. Clin. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/7\/1090\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T19:25:45Z","timestamp":1760210745000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/17\/7\/1090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,8]]},"references-count":40,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2016,7]]}},"alternative-id":["ijms17071090"],"URL":"https:\/\/doi.org\/10.3390\/ijms17071090","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,8]]}}}